Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT05832008 Recruiting - Lung Cancer Clinical Trials

Increasing Adherence to Lung Cancer Screening

Start date: October 18, 2023
Phase: N/A
Study type: Interventional

Investigators are conducting a pragmatic randomized trial testing the effectiveness of patient and clinician nudge strategies on adherence to lung cancer screening (LCS) & diagnostic follow-up across eligible primary care clinicians & patients. Following the trial, a subsample of patients & clinicians will be invited to one-time semi-structured interview & survey to identify individual & system-level factors that may restrict or enhance the impact of strategies.

NCT ID: NCT05824273 Recruiting - Lung Cancer Clinical Trials

The INSPIRE-Lung Study

Start date: August 2, 2023
Phase: N/A
Study type: Interventional

LungTalk and leveraging Facebook-targeted Advertisement (FBTA) addresses the call to develop and test multi-level, cancer communication interventions using innovative methods and designs. The study's long term goal is to increase lung cancer screening uptake among appropriate, high-risk individuals nationwide.

NCT ID: NCT05807022 Not yet recruiting - Lung Cancer Clinical Trials

Evaluation of the Safety and Effectiveness of Percutaneous and Transbronchial Argon-helium Cryoablation

Start date: March 30, 2023
Phase: N/A
Study type: Interventional

The goal clinical trial is to evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation in primary lung cancer and metastatic lung cancer. The main question it aims to answer are:Evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation. Participants will undergo percutaneous or transbronchial argon-helium cryoablation.

NCT ID: NCT05804786 Recruiting - Lung Cancer Clinical Trials

Prospective Cohort of Diagnostic Bronchoscopy for Peripheral Lung Lesions

Start date: April 1, 2023
Phase:
Study type: Observational

The primary objective is To evaluate the usefulness and safety of advanced guided bronchoscopy for histological diagnosis of peripheral pulmonary lesions. The Secondary objective is to establish a strategy that can most effectively use endoscopes for early diagnosis of lung cancer in a real-world care environment by identifying patient/clinical/image/procedure-related characteristics that can optimize the practicality of emerging technologies.

NCT ID: NCT05803746 Recruiting - Colorectal Cancer Clinical Trials

PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor

Start date: July 15, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to construct a noninvasive approach using 68Ga- Mirc415 PET/CT to detect the PD-L2 expression of tumor lesion in patients with colorectal cancer, lung cancer and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.

NCT ID: NCT05802641 Active, not recruiting - Lung Cancer Clinical Trials

Stereotactic Radiotherapy With Different Fractionation Modes for the Early Lung Cancer

DSBRT-1
Start date: January 7, 2018
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) with different fractionation modes for early lung cancer. The main questions it aims to answer are: How effective are different regimens of SBRT for early lung cancer? How safe are different regimens of SBRT of SBRT for early lung cancer?

NCT ID: NCT05801965 Active, not recruiting - Prostate Cancer Clinical Trials

A Digital Therapeutic Solution for Cancer Patients

Start date: April 6, 2023
Phase: N/A
Study type: Interventional

This is a randomized, controlled trial to assess the feasibility of Sidekick Health's digital programs for cancer patients. Participants will be treated with standard of care (SoC) in combination with the digital programs, or SoC only. We will compare the effect of the digital programs in addition to SoC to SoC only, on the cancer-related quality of life (QoL), cancer-related fatigue, and side-effect management.

NCT ID: NCT05801406 Recruiting - Lung Cancer Clinical Trials

From Benchmark to Surgical Activity: the Role of Endobronchial Fiducial Markers for Ground Glass Lung Nodules Resection.

Vortex_US
Start date: March 24, 2023
Phase:
Study type: Observational [Patient Registry]

With the risen popularity of low-dose computed tomography (LDCT) for lung cancer screening, many patients present with peripheral pulmonary ground-glass nodules (GGNs) with a suspicious solid part. The appropriate diagnostic and management strategy for those lesions can be questionable. If malignancy is suspected, a surgical biopsy with the guidance of various localization methods available is recommended. Each localization method has its advantages and disadvantages. Therefore, it may not be possible to establish a gold standard for localizing indeterminate lung nodules since comparative clinical trials are lacking.

NCT ID: NCT05801133 Recruiting - Lung Cancer Clinical Trials

Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors

Start date: March 31, 2023
Phase: Phase 2
Study type: Interventional

Patients with advanced lung cancer who have previously received immunocheckpoint inhibitor therapy, undergone chest radiation therapy again have developed radiation induced lung injury. Pirfenidone has anti-inflammatory and anti fibrosis effects. This study is intended to evaluate the effectiveness of pirfenidone combined with radiotherapy in the prevention of radiation pneumonitis.

NCT ID: NCT05800587 Recruiting - Lung Cancer Clinical Trials

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Start date: February 22, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.